Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 1/20 | 0.62 |
| ▸ | HTT | P42858 | 1/20 | 0.62 |
| ▸ | FOLH1 | Q04609 | 4/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.57 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.57 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.56 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.56 |
| ▸ | MMP2 | P08253 | 1/20 | 0.56 |
| ▸ | MMP9 | P14780 | 1/20 | 0.56 |
| ▸ | ANPEP | P15144 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6827180 | 0.92 | TGM2 (0.62) | TGM2HTTFOLH1LMNASMN1; SMN2 | |
| SCHEMBL6827355 | 0.92 | TGM2 (0.62) | TGM2HTTFOLH1LMNASMN1; SMN2 | |
| SCHEMBL6827174 | 0.92 | TGM2 (0.62) | TGM2HTTFOLH1LMNASMN1; SMN2 | |
| SCHEMBL11758185 | 0.91 | HTT (0.58) | TGM2HTTFOLH1LMNASMN1; SMN2 | |
| SCHEMBL318935 | 0.90 | HTT (0.63) | TGM2HTTFOLH1LMNASMN1; SMN2 | |
| SCHEMBL318936 | 0.90 | HTT (0.63) | TGM2HTTFOLH1LMNASMN1; SMN2 | |
| SCHEMBL6827224 | 0.90 | HTT (0.63) | TGM2HTTFOLH1LMNASMN1; SMN2 | |
| SCHEMBL25961940 | 0.89 | TGM2 (0.65) | TGM2HTTFOLH1LMNASMN1; SMN2 | |
| SCHEMBL16219553 | 0.89 | TGM2 (0.65) | TGM2HTTFOLH1LMNASMN1; SMN2 | |
| SCHEMBL15346534 | 0.87 | HTT (0.79) | TGM2HTTFOLH1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6737416-B2 | THROMBOLYTIC AGENT HAVING HIGHER SAFETY | MEIJI SEIKA KAISHA LTD. (JP) | 2004-05-18 | — | — | US | disclosed |
| US-20030119787-A1 | Phosphonic acid derivative having inhibitory activity against carboxypeptidase B | MEIJI SEIKA KAISHA LTD. (JP) | 2003-06-26 | — | — | US | disclosed |
| US-6576627-B1 | Such as 7-amino-2-((2-methyl-1-(3-phenylpropanoylamino)-propyl)hydroxyphosphinoyl) -methylheptanoic acid; thrombotic disease | MEIJI SEIKA KAISHA LTD. (JP) | 2003-06-10 | — | — | US | disclosed |
| EP-1152004-B1 | Phosphonic acid derivatives having carboxypeptidase B inhibitory action | MEIJI SEIKA KAISHA (JP) | 2003-05-07 | — | — | EP | disclosed |
| EP-1174434-A1 | Phosphonic acid derivative having inhibitory activity against carboxypeptidase B | MEIJI SEIKA KAISHA LTD. (JP) | 2002-01-23 | — | — | EP | disclosed |
| EP-1152004-A1 | PHOSPHONIC ACID DERIVATIVES HAVING CARBOXYPEPTIDASE B INHIBITORY ACTIVITY | MEIJI SEIKA KAISHA LTD. (JP) | 2001-11-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030119787-A1 | Phosphonic acid derivative having inhibitory activity against carboxypeptidase B | CPB1, RNPEP, CPN1 | TGM2 903/4885HTT 3437/4885FOLH1 73/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.